150543 20260219074026.0 GASTROENTEROLOGY & HEPATOLOGY 12 / 148 = 0.081 2024 Q1 T1 8.7 2024 Medicine (miscellaneous) 2024 Q1 Gastroenterology 2024 Q1 2.991 2024 15.6 2024 ARTICLE (orcid)0000-0003-0076-3529 Gomollón, Fernando Universidad de Zaragoza Louro, Javier López Pérez, Juan Nocito Colon, María Mercedes Gallego Llera, Beatriz García-Mateo, Sandra Universidad de Zaragoza Martínez-Domínguez, Samuel J Universidad de Zaragoza (orcid)0000-0002-9962-6147 Aso Gonzalvo, María Concepción (orcid)0000-0002-3545-2707 Gargallo-Puyuelo, Carla J Universidad de Zaragoza ART-2024-142601 733876 http://zaguan.unizar.es/record/150543/files/texto_completo.pdf Versión publicada info:eu-repo/date/embargoEnd/2025-11-21 2064902 http://zaguan.unizar.es/record/150543/files/texto_completo.jpg?subformat=icon icon Versión publicada info:eu-repo/date/embargoEnd/2025-11-21 2026-02-17-20:39:27 info:eu-repo/semantics/openAccess All rights reserved http://www.europeana.eu/rights/rr-f/ info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Background: HLADQA1*05 is recently associated with heightened immunogenicity to anti-tumor necrosis factor (TNFα). We aimed to determine whether HLADQ1*05 is a risk factor for primary non-response, loss of response (LOR), or adverse events (AE) to first-line anti-TNFα in patients with inflammatory bowel disease. Methods: We performed a retrospective observational study enrolling biologic naïve patients with Crohn’s disease and ulcerative colitis who initiated adalimumab or infliximab from 2000 to 2021. HLA-DQA1 genotype was determined in all patients and immunogenicity in 98 patients. Results: We enrolled 408 patients who started first-line infliximab (n = 211) and adalimumab (n = 197), with a mean follow-up of 7.6 years. Primary response at Week 24 occurred in 347 (85.0%), LOR in 133 (38.3%), and AE in 93 (22.8%). The HLADQA1*05 was identified in 185 (43.3%) patients. In multivariate analyses, no risk factors were identified for primary response. HLADQA1*05 was an independent risk factor for LOR (adjusted hazard ratio [aHR] = 1.80, 95% CI = 1.21-2.67) and immunogenicity (aOR = 3.44, 95% CI = 1.12-11.92). HLADQA1*03 was a protective factor against LOR (aHR = 0.42, 95% CI = 0.20-0.88). Stratified analysis by anti-TNF type showed that HLADQA1*05 increased the risk of LOR to infliximab but not to adalimumab and HLADQA1*03 decreased the risk of LOR to adalimumab but not to infliximab. Female sex, infliximab, and the co-presentation of at least one allele of the HLADQA1*03 and HLADQA1*05 were risk factors for AE. Conclusions: HLADQA1*05 is associated with a higher risk of LOR and immunogenicity, particularly to infliximab. HLADQA1*03 seems to play a protective role against LOR, particularly adalimumab. Female sex and infliximab are risk factors for AE. 20 (2024), 1-10 J. Crohns Colitis Journal of Crohn's & colitis 1873-9946 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina Impact of HLADQA1*05 and HLADQA1*03 on Safety and Loss of Response to Anti-Tumor Necrosis Factor in Patients With Inflammatory Bowel Disease doi 10.1093/ecco-jcc/jjae178 sideral 142601 2024 (orcid)0000-0002-2945-7368 López De-La-Cruz, Julia eng oai:zaguan.unizar.es:150543 articulos driver